文献速递妇科

腹主动脉旁淋巴结切除术能否改善病理诊断的早期3级子宫内膜样及非子宫内膜样子宫内膜癌生存?韩国与台湾的回顾性队列研究

Does para-aortic lymphadenectomy improve survival in pathologically diagnosed early-stage grade 3 endometrioid and non-endometrioid endometrial cancers? A retrospective cohort study in Korea and Taiwan.
PubMed 文献 · Gynecol Oncol · 2022-08-20

该回顾性队列研究纳入韩国和台湾两个三级中心的281例病理确诊FIGO I-II期3级子宫内膜样及非子宫内膜样子宫内膜癌患者,比较单纯盆腔淋巴结切除术与联合盆腔及腹主动脉旁淋巴结切除术的生存差异。中位随访45个月,两组无复发生存和总生存均无显著差异,联合组未见生存获益。

要点

  • 在FIGO I-II期3级子宫内膜样及非子宫内膜样子宫内膜癌中,联合盆腔及腹主动脉旁淋巴结切除术较单纯盆腔淋巴结切除术未改善无复发生存和总生存。
  • 多因素分析中,诊断年龄≥60岁(HR=2.20)和LVSI阳性(HR=2.79)与更差的无复发生存相关。
  • 仅非子宫内膜样组织学与更差的总生存相关(HR=3.18)。

核心结论

  • 在FIGO I-II期3级子宫内膜样及非子宫内膜样子宫内膜癌患者中,联合盆腔及腹主动脉旁淋巴结切除术较单纯盆腔淋巴结切除术未能改善生存。
  • 作者认为,对这些病例可省略腹主动脉旁淋巴结切除术。

研究设计与样本

  • 回顾性队列研究,纳入韩国和台湾两个三级中心共281例病理确诊FIGO I-II期3级子宫内膜样及非子宫内膜样子宫内膜癌患者。
  • 144例接受单纯盆腔淋巴结切除术,137例接受联合盆腔及腹主动脉旁淋巴结切除术。

主要发现

  • 中位随访45个月,两组无复发生存和总生存均无显著差异。
  • 多因素分析中,诊断年龄≥60岁(HR=2.20,95%CI 1.25-3.87,p=0.006)和LVSI阳性(HR=2.79,95%CI 1.60-4.85,p<0.001)与更差的无复发生存相关。
  • 仅非子宫内膜样组织学与更差的总生存相关(HR=3.18,95%CI 1.42-7.12,p=0.005)。
  • 亚组分析中未观察到联合盆腔及腹主动脉旁淋巴结切除术对无复发生存和总生存的获益效应。

临床怎么用

  • 作者认为,对于FIGO I-II期3级子宫内膜样及非子宫内膜样子宫内膜癌病例,可省略腹主动脉旁淋巴结切除术。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The therapeutic effect of para-aortic lymphadenectomy in early-stage high-grade endometrial cancer remains controversial. In this study, we investigated whether combined pelvic and para-aortic lymphadenectomy has a survival benefit compared to pelvic lymphadenectomy alone in patients with pathologically diagnosed FIGO stage I-II grade 3 endometrioid and non-endometrioid endometrial cancers. METHODS: We retrospectively reviewed the medical records of 281 patients with histologically confirmed FIGO stage I-II grade 3 endometrioid and non-endometrioid endometrial cancers who underwent pelvic lymphadenectomy alone or combined pelvic and para-aortic lymphadenectomy in staging surgery at two tertiary centers in Korea and Taiwan. Prognostic factors to predict outcomes in these cases were also analyzed. RESULTS: Among 281 patients, 144 underwent pelvic lymphadenectomy alone and 137 underwent combined pelvic and para-aortic lymphadenectomy. Within a median follow-up of 45 months, there was no significant difference in recurrence-free survival (RFS) and overall survival (OS) between the two groups. In multivariable analysis, age at diagnosis ≥60 years (HR = 2.20, 95% CI 1.25-3.87, p = 0.006) and positive lymph-vascular space invasion (LVSI) (HR = 2.79, 95% CI 1.60-4.85, p < 0.001) were associated with worse RFS, and only non-endometrioid histology was associated with worse OS (HR = 3.18, 95% CI 1.42-7.12, p = 0.005). In further subgroup analysis, beneficial effects of combined pelvic and para-aortic lymphadenectomy on RFS and OS were not observed. CONCLUSIONS: In this study, combined pelvic and para-aortic lymphadenectomy could not improve survival compared to pelvic lymphadenectomy alone in patients with FIGO stage I-II grade 3 endometrioid and non-endometrioid endometrial cancers. Therefore, para-aortic lymphadenectomy may be omitted for these cases.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Lai YL, Chang CS, Chang K, et al. Does para-aortic lymphadenectomy improve survival in pathologically diagnosed early-stage grade 3 endometrioid and non-endometrioid endometrial cancers? A retrospective cohort study in Korea and Taiwan. Gynecol Oncol. 2022. PMID: 35995599. doi:10.1016/j.ygyno.2022.08.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。